Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,3624392,limit of detection,The limit of detection of the method is 5 ng/ml for zopiclone in plasma and urine and 10 ng/ml for its two main metabolites (coefficient of variation less than 10%).,Simultaneous determination of zopiclone and its two major metabolites (N-oxide and N-desmethyl) in human biological fluids by reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3624392/),[ng] / [ml],5,5769,DB01198,Zopiclone
,3624392,limit of detection,The limit of detection of the method is 5 ng/ml for zopiclone in plasma and urine and 10 ng/ml for its two main metabolites (coefficient of variation less than 10%).,Simultaneous determination of zopiclone and its two major metabolites (N-oxide and N-desmethyl) in human biological fluids by reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3624392/),[ng] / [ml],10,5770,DB01198,Zopiclone
less,3624392,limit of detection,The limit of detection of the method is 5 ng/ml for zopiclone in plasma and urine and 10 ng/ml for its two main metabolites (coefficient of variation less than 10%).,Simultaneous determination of zopiclone and its two major metabolites (N-oxide and N-desmethyl) in human biological fluids by reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3624392/),,10,5771,DB01198,Zopiclone
,9159561,total area under the plasma z,The total area under the plasma zopiclone concentration-time curve after rifampicin was 18.0% (95% CI 13.5-22.5%) of that after placebo (86.1 +/- 34.5 ng ml(-1) h vs 473 +/- 114 ng ml(-1) h (mean +/- s.d.); P<0.001).,Concentrations and effects of zopiclone are greatly reduced by rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159561/),[h·ng] / [ml],86.1,20158,DB01198,Zopiclone
,9159561,total area under the plasma z,The total area under the plasma zopiclone concentration-time curve after rifampicin was 18.0% (95% CI 13.5-22.5%) of that after placebo (86.1 +/- 34.5 ng ml(-1) h vs 473 +/- 114 ng ml(-1) h (mean +/- s.d.); P<0.001).,Concentrations and effects of zopiclone are greatly reduced by rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159561/),[h·ng] / [ml],473,20159,DB01198,Zopiclone
,9159561,peak plasma concentration,Rifampicin decreased the peak plasma concentration of zopiclone from 76.9 +/- 27.2 ng ml(-1) to 22.5 +/- 6.0 ng ml(-1) (P<0.001) and the half-life from 3.8 +/- 0.6 h to 2.3 +/- 0.9 h (P<0.005).,Concentrations and effects of zopiclone are greatly reduced by rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159561/),[ng] / [ml],76.9,20160,DB01198,Zopiclone
,9159561,peak plasma concentration,Rifampicin decreased the peak plasma concentration of zopiclone from 76.9 +/- 27.2 ng ml(-1) to 22.5 +/- 6.0 ng ml(-1) (P<0.001) and the half-life from 3.8 +/- 0.6 h to 2.3 +/- 0.9 h (P<0.005).,Concentrations and effects of zopiclone are greatly reduced by rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159561/),[ng] / [ml],22.5,20161,DB01198,Zopiclone
,9159561,half-life,Rifampicin decreased the peak plasma concentration of zopiclone from 76.9 +/- 27.2 ng ml(-1) to 22.5 +/- 6.0 ng ml(-1) (P<0.001) and the half-life from 3.8 +/- 0.6 h to 2.3 +/- 0.9 h (P<0.005).,Concentrations and effects of zopiclone are greatly reduced by rifampicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159561/),h,3.8,20162,DB01198,Zopiclone
,9159561,half-life,Rifampicin decreased the peak plasma concentration of zopiclone from 76.9 +/- 27.2 ng ml(-1) to 22.5 +/- 6.0 ng ml(-1) (P<0.001) and the half-life from 3.8 +/- 0.6 h to 2.3 +/- 0.9 h (P<0.005).,Concentrations and effects of zopiclone are greatly reduced by rifampicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159561/),h,2.3,20163,DB01198,Zopiclone
exceeding,23981345,half-life,"DORAs, with a half-life exceeding 8 h in humans, are expected to fulfill this requirement as exposures drop to sub-threshold receptor occupancy levels prior to the wake period, potentially avoiding next-day residual effects at therapeutic doses.",The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23981345/),h,8,48929,DB01198,Zopiclone
,7905394,AUC0-->infinity,Determination of concentrations of zopiclone enantiomers in plasma showed that zopiclone pharmacokinetics is stereoselective with AUC0-->infinity values of 691.3 and 209.5 ng.,Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905394/),ng,691.3,50776,DB01198,Zopiclone
,7905394,AUC0-->infinity,Determination of concentrations of zopiclone enantiomers in plasma showed that zopiclone pharmacokinetics is stereoselective with AUC0-->infinity values of 691.3 and 209.5 ng.,Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905394/),ng,209.5,50777,DB01198,Zopiclone
,7905394,Cmax,"ml-1.hr (p < 0.001), Cmax values of 87.3 and 44.0 ng.",Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905394/),ng,87.3,50778,DB01198,Zopiclone
,7905394,Cmax,"ml-1.hr (p < 0.001), Cmax values of 87.3 and 44.0 ng.",Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905394/),ng,44.0,50779,DB01198,Zopiclone
,7905394,oral CLtot/F,"ml-1 (p < 0.001), oral CLtot/F values of 195.5 and 659.8 ml.min-1 (p < 0.001), Vd/F values of 98.6 and 192.8 liters (p < 0.01) and elimination half-life of 399.2 and 225.6 min (p < 0.01) for (+)-zopiclone and (-)-zopiclone, respectively.",Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905394/),[ml] / [min],195.5,50780,DB01198,Zopiclone
,7905394,oral CLtot/F,"ml-1 (p < 0.001), oral CLtot/F values of 195.5 and 659.8 ml.min-1 (p < 0.001), Vd/F values of 98.6 and 192.8 liters (p < 0.01) and elimination half-life of 399.2 and 225.6 min (p < 0.01) for (+)-zopiclone and (-)-zopiclone, respectively.",Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905394/),[ml] / [min],659.8,50781,DB01198,Zopiclone
,7905394,Vd/F,"ml-1 (p < 0.001), oral CLtot/F values of 195.5 and 659.8 ml.min-1 (p < 0.001), Vd/F values of 98.6 and 192.8 liters (p < 0.01) and elimination half-life of 399.2 and 225.6 min (p < 0.01) for (+)-zopiclone and (-)-zopiclone, respectively.",Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905394/),l,98.6,50782,DB01198,Zopiclone
,7905394,Vd/F,"ml-1 (p < 0.001), oral CLtot/F values of 195.5 and 659.8 ml.min-1 (p < 0.001), Vd/F values of 98.6 and 192.8 liters (p < 0.01) and elimination half-life of 399.2 and 225.6 min (p < 0.01) for (+)-zopiclone and (-)-zopiclone, respectively.",Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905394/),l,192.8,50783,DB01198,Zopiclone
,7905394,elimination half-life,"ml-1 (p < 0.001), oral CLtot/F values of 195.5 and 659.8 ml.min-1 (p < 0.001), Vd/F values of 98.6 and 192.8 liters (p < 0.01) and elimination half-life of 399.2 and 225.6 min (p < 0.01) for (+)-zopiclone and (-)-zopiclone, respectively.",Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905394/),min,399.2,50784,DB01198,Zopiclone
,7905394,elimination half-life,"ml-1 (p < 0.001), oral CLtot/F values of 195.5 and 659.8 ml.min-1 (p < 0.001), Vd/F values of 98.6 and 192.8 liters (p < 0.01) and elimination half-life of 399.2 and 225.6 min (p < 0.01) for (+)-zopiclone and (-)-zopiclone, respectively.",Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905394/),min,225.6,50785,DB01198,Zopiclone
,28886938,Rs,"An excellent chiral separation (Rs=5.0) was achieved using a chiral stationary phase comprising cellulose tris(3,5-dichlorophenylcarbamate) and a volatile mobile phase of 10mM ammonium carbonate (pH 8.0)-acetonitrile (25:75, v/v).",Enantioselective determination of (R)-zopiclone and (S)-zopiclone (eszopiclone) in human hair by micropulverized extraction and chiral liquid chromatography/high resolution mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28886938/),,5.0,63126,DB01198,Zopiclone
,9010708,Cmax,Itraconazole significantly increased the Cmax of zopiclone from 49 to 63 ng.,Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010708/),ng,49,92194,DB01198,Zopiclone
,9010708,Cmax,Itraconazole significantly increased the Cmax of zopiclone from 49 to 63 ng.,Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010708/),ng,63,92195,DB01198,Zopiclone
,9010708,t 1/2,The t 1/2 of zopiclone was prolonged from 5.0 to 7.0 h.,Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010708/),h,5,92196,DB01198,Zopiclone
,9010708,AUC(0-inifinity),The AUC(0-inifinity) of zopiclone was increased from 415 to 719 ng.,Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010708/),ng,415,92197,DB01198,Zopiclone
,9010708,AUC(0-inifinity),The AUC(0-inifinity) of zopiclone was increased from 415 to 719 ng.,Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010708/),ng,719,92198,DB01198,Zopiclone
,8634767,detection limits,"The detection limits are 1 and 2 ng/ml for zolpidem and zopiclone, respectively.",Simultaneous determination of zolpidem and zopiclone in human plasma by gas chromatography-nitrogen-phosphorus detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8634767/),[ng] / [ml],1,96810,DB01198,Zopiclone
,8634767,detection limits,"The detection limits are 1 and 2 ng/ml for zolpidem and zopiclone, respectively.",Simultaneous determination of zolpidem and zopiclone in human plasma by gas chromatography-nitrogen-phosphorus detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8634767/),[ng] / [ml],2,96811,DB01198,Zopiclone
,3413208,half-life,Pharmacokinetic properties class ZPC in the category of hypnotics with intermediate-short half-life (5-7 hours) and explain the low incidence of unwanted effects reported.,"Zopiclone, a cyclopyrrolone hypnotic: review of properties. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3413208/),h,5-7,97480,DB01198,Zopiclone
,6743780,elimination half-life,The average elimination half-life was 3.8 +/- 0.2 h.,Pharmacokinetic and clinical parameters of zopiclone and trimipramine when administered simultaneously to volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6743780/),h,3.8,100733,DB01198,Zopiclone
,8737972,clearance,"The median (range) values for clearance, volume of distribution and elimination half-life were 21 (15-53) L/hr, 132 (58-161) L and 3.4 (1.7-5.7) hr, respectively.",Pharmacokinetic-pharmacodynamic modelling of zopiclone effects on human central nervous system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8737972/),[l] / [h],21,101720,DB01198,Zopiclone
,8737972,volume of distribution,"The median (range) values for clearance, volume of distribution and elimination half-life were 21 (15-53) L/hr, 132 (58-161) L and 3.4 (1.7-5.7) hr, respectively.",Pharmacokinetic-pharmacodynamic modelling of zopiclone effects on human central nervous system. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8737972/),l,132,101721,DB01198,Zopiclone
,8737972,elimination half-life,"The median (range) values for clearance, volume of distribution and elimination half-life were 21 (15-53) L/hr, 132 (58-161) L and 3.4 (1.7-5.7) hr, respectively.",Pharmacokinetic-pharmacodynamic modelling of zopiclone effects on human central nervous system. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8737972/),h,3.4,101722,DB01198,Zopiclone
,19300573,elimination half-life,"Peak plasma concentrations are attained 1.0-1.6 hours after a 3 mg dose, while the mean elimination half-life is 6 hours.",Eszopiclone: its use in the treatment of insomnia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19300573/),h,6,108429,DB01198,Zopiclone
,19300573,half-life,The half-life increases with age to about 9.0 hours in patients 65 years or older.,Eszopiclone: its use in the treatment of insomnia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19300573/),h,9.0,108430,DB01198,Zopiclone
,3988401,peak plasma,"The peak plasma zopiclone concentration (65 ng/ml) occurred at 1.4 h after dosing and thereafter declined by a biexponential process, with half-lives of 2.0 and 6.5 h, to 3 ng/ml by 24 h after dosing.","A repeated dose pharmacokinetic study of a new hypnotic agent, zopiclone (Imovane). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988401/),[ng] / [ml],65,114255,DB01198,Zopiclone
,3988401,half-lives,"The peak plasma zopiclone concentration (65 ng/ml) occurred at 1.4 h after dosing and thereafter declined by a biexponential process, with half-lives of 2.0 and 6.5 h, to 3 ng/ml by 24 h after dosing.","A repeated dose pharmacokinetic study of a new hypnotic agent, zopiclone (Imovane). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988401/),h,2.0,114256,DB01198,Zopiclone
,3988401,half-lives,"The peak plasma zopiclone concentration (65 ng/ml) occurred at 1.4 h after dosing and thereafter declined by a biexponential process, with half-lives of 2.0 and 6.5 h, to 3 ng/ml by 24 h after dosing.","A repeated dose pharmacokinetic study of a new hypnotic agent, zopiclone (Imovane). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988401/),h,6.5,114257,DB01198,Zopiclone
,3988401,half-lives,"The peak plasma zopiclone concentration (65 ng/ml) occurred at 1.4 h after dosing and thereafter declined by a biexponential process, with half-lives of 2.0 and 6.5 h, to 3 ng/ml by 24 h after dosing.","A repeated dose pharmacokinetic study of a new hypnotic agent, zopiclone (Imovane). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988401/),[ng] / [ml],3,114258,DB01198,Zopiclone
,29396378,Limit of detection,"Limit of detection has been obtained as 0.083μg/mL and 0.472μg/mL respectively, for HPLC and UV-Visible techniques, corresponding to assessed linearity range.","Cloud point extraction coupled with microwave-assisted back-extraction (CPE-MABE) for determination of Eszopiclone (Z-drug) using UV-Visible, HPLC and mass spectroscopic (MS) techniques: Spiked and in vivo analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29396378/),[μg] / [ml],0.083,119382,DB01198,Zopiclone
,29396378,Limit of detection,"Limit of detection has been obtained as 0.083μg/mL and 0.472μg/mL respectively, for HPLC and UV-Visible techniques, corresponding to assessed linearity range.","Cloud point extraction coupled with microwave-assisted back-extraction (CPE-MABE) for determination of Eszopiclone (Z-drug) using UV-Visible, HPLC and mass spectroscopic (MS) techniques: Spiked and in vivo analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29396378/),[μg] / [ml],0.472,119383,DB01198,Zopiclone
,29396378,extraction recovery,"Under optimized conditions i.e. Aqueous-Triton X-114 4% (w/v), pH4.0, NaCl 4% (w/v) and equilibrium temperature of 45°C for 20min, average extraction recovery has been obtained between 89.8 and 99.2% and 84.0-99.2% from UV-Visible and HPLC analysis, respectively.","Cloud point extraction coupled with microwave-assisted back-extraction (CPE-MABE) for determination of Eszopiclone (Z-drug) using UV-Visible, HPLC and mass spectroscopic (MS) techniques: Spiked and in vivo analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29396378/),%,89.8 and 99.2,119384,DB01198,Zopiclone
,29396378,extraction recovery,"Under optimized conditions i.e. Aqueous-Triton X-114 4% (w/v), pH4.0, NaCl 4% (w/v) and equilibrium temperature of 45°C for 20min, average extraction recovery has been obtained between 89.8 and 99.2% and 84.0-99.2% from UV-Visible and HPLC analysis, respectively.","Cloud point extraction coupled with microwave-assisted back-extraction (CPE-MABE) for determination of Eszopiclone (Z-drug) using UV-Visible, HPLC and mass spectroscopic (MS) techniques: Spiked and in vivo analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29396378/),%,84.0-99.2,119385,DB01198,Zopiclone
,8521677,absolute bio-availability,Zolpidem is approximately 92% bound to plasma proteins; absolute bio-availability of zolpidem is about 70%.,Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),%,70,127592,DB01198,Zopiclone
,8521677,peak plasma concentration,"After single 20mg oral doses, typical values of pharmacokinetic variables for zolpidem in humans are: a peak plasma concentration of 192 to 324 micrograms/L occurring 0.75 to 2.6 hours postdose; a terminal elimination half-line of 1.5 to 3.2 hours; and total clearance of 0.24 to 0.27 ml/min/kg.",Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),[μg] / [l],192 to 324,127593,DB01198,Zopiclone
,8521677,terminal elimination half-line,"After single 20mg oral doses, typical values of pharmacokinetic variables for zolpidem in humans are: a peak plasma concentration of 192 to 324 micrograms/L occurring 0.75 to 2.6 hours postdose; a terminal elimination half-line of 1.5 to 3.2 hours; and total clearance of 0.24 to 0.27 ml/min/kg.",Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),h,1.5 to 3.2,127594,DB01198,Zopiclone
,8521677,total clearance,"After single 20mg oral doses, typical values of pharmacokinetic variables for zolpidem in humans are: a peak plasma concentration of 192 to 324 micrograms/L occurring 0.75 to 2.6 hours postdose; a terminal elimination half-line of 1.5 to 3.2 hours; and total clearance of 0.24 to 0.27 ml/min/kg.",Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),[ml] / [kg·min],0.24 to 0.27,127595,DB01198,Zopiclone
,9949479,peak serum concentration,"To detect and quantify clozapine in plasma, high-pressure liquid chromatography showed a 4 h absorption phase and a peak serum concentration of 5200 ng/ml.",Non-fatal clozapine (LEPONEX) intoxication with toxicokinetic evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9949479/),[ng] / [ml],5200,132409,DB01198,Zopiclone
,9949479,elimination t1/2,"Three successive elimination t1/2 values of 38, 24 and 13 h were calculated.",Non-fatal clozapine (LEPONEX) intoxication with toxicokinetic evaluation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9949479/),h,38,132410,DB01198,Zopiclone
,9949479,elimination t1/2,"Three successive elimination t1/2 values of 38, 24 and 13 h were calculated.",Non-fatal clozapine (LEPONEX) intoxication with toxicokinetic evaluation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9949479/),h,24,132411,DB01198,Zopiclone
,9949479,elimination t1/2,"Three successive elimination t1/2 values of 38, 24 and 13 h were calculated.",Non-fatal clozapine (LEPONEX) intoxication with toxicokinetic evaluation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9949479/),h,13,132412,DB01198,Zopiclone
,21618564,total run time,"The total run time was 1.5 min and the elution of ESZ and IS occurred at 0.90 min; this was achieved with a mobile phase consisting of 0.1% formic acid-methanol (15:85, v/v) at a flow rate of 0.50 mL/min on a Discover C(18) (50 × 4.6 mm, 5 µm) column.",A rapid LC-MS/MS method for quantitation of eszopiclone in human plasma: application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21618564/),min,1.5,133948,DB01198,Zopiclone
,21618564,flow rate,"The total run time was 1.5 min and the elution of ESZ and IS occurred at 0.90 min; this was achieved with a mobile phase consisting of 0.1% formic acid-methanol (15:85, v/v) at a flow rate of 0.50 mL/min on a Discover C(18) (50 × 4.6 mm, 5 µm) column.",A rapid LC-MS/MS method for quantitation of eszopiclone in human plasma: application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21618564/),[ml] / [min],0.50,133949,DB01198,Zopiclone
,3438645,Tmax,"In 45 healthy young volunteers, zopiclone had a Tmax of 0.5.",Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438645/),,0.5,147614,DB01198,Zopiclone
,3438645,"absolute bioavailability, F","A first-pass effect of 20% resulted in an absolute bioavailability, F, of 77%.",Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438645/),%,77,147615,DB01198,Zopiclone
,3438645,volume of distribution ratio Vdc/Vdt,The volume of distribution ratio Vdc/Vdt was 3.2.,Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438645/),,3.2,147616,DB01198,Zopiclone
,3438645,plasma half-life (t1/2),The plasma half-life (t1/2) was 5.1 h.,Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438645/),h,5.1,147617,DB01198,Zopiclone
,3438645,metabolic ratio,"A metabolic ratio of 3.7 and 4.6 was found for the two main urinary metabolites, N-oxide and N-desmethyl derivatives.",Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438645/),,3,147618,DB01198,Zopiclone
,3438645,Tmax,"In eight patients with liver insufficiency, the main changes (delayed Tmax, 3.5 h, higher plasma concentrations with an increased F of 97%, prolonged t1/2 of 8.4 h) were essentially due to a reduced hepatic metabolic clearance, as shown by a decreased metabolic ratio for the two main metabolites.",Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438645/),h,3.5,147619,DB01198,Zopiclone
,3438645,t1/2,"In eight patients with liver insufficiency, the main changes (delayed Tmax, 3.5 h, higher plasma concentrations with an increased F of 97%, prolonged t1/2 of 8.4 h) were essentially due to a reduced hepatic metabolic clearance, as shown by a decreased metabolic ratio for the two main metabolites.",Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438645/),h,8.4,147620,DB01198,Zopiclone
,3438645,bioavailability (F,"In 18 patients with renal insufficiency, the only major modification was an increased bioavailability (F of 115%) probably due to a relative decrease of the Vdc.",Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438645/),%,115,147621,DB01198,Zopiclone
,3438645,plasma t1/2,The increase in F (168%) and the age-dependent increase in plasma t1/2 (8.1 h) in the oldest subjects (over 74 years of age) can be explained by this double mechanism.,Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438645/),h,8.1,147622,DB01198,Zopiclone
,2387982,elimination half-life,Zopiclone is a new hypnotic cyclopyrrolone with a short elimination half-life (5.3 h).,Steady state pharmacokinetics of zopiclone during multiple oral dosing (7.5 mg nocte) in patients with severe chronic renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387982/),h,5.3,151270,DB01198,Zopiclone
,2387982,C max,C max and T max were not significantly different between the two groups but the C min of unchanged zopiclone (at 24 h) post-dosing was significantly (p less than 0.001) higher in CRF patients (8.16 +/- 5.34 ng/ml) than in healthy volunteers (1.90 +/- 0.82 ng/ml).,Steady state pharmacokinetics of zopiclone during multiple oral dosing (7.5 mg nocte) in patients with severe chronic renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387982/),[ng] / [ml],8.16,151271,DB01198,Zopiclone
,2387982,T max,C max and T max were not significantly different between the two groups but the C min of unchanged zopiclone (at 24 h) post-dosing was significantly (p less than 0.001) higher in CRF patients (8.16 +/- 5.34 ng/ml) than in healthy volunteers (1.90 +/- 0.82 ng/ml).,Steady state pharmacokinetics of zopiclone during multiple oral dosing (7.5 mg nocte) in patients with severe chronic renal failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387982/),[ng] / [ml],8.16,151272,DB01198,Zopiclone
,2387982,C min,C max and T max were not significantly different between the two groups but the C min of unchanged zopiclone (at 24 h) post-dosing was significantly (p less than 0.001) higher in CRF patients (8.16 +/- 5.34 ng/ml) than in healthy volunteers (1.90 +/- 0.82 ng/ml).,Steady state pharmacokinetics of zopiclone during multiple oral dosing (7.5 mg nocte) in patients with severe chronic renal failure. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387982/),[ng] / [ml],8.16,151273,DB01198,Zopiclone
,2387982,C min,C max and T max were not significantly different between the two groups but the C min of unchanged zopiclone (at 24 h) post-dosing was significantly (p less than 0.001) higher in CRF patients (8.16 +/- 5.34 ng/ml) than in healthy volunteers (1.90 +/- 0.82 ng/ml).,Steady state pharmacokinetics of zopiclone during multiple oral dosing (7.5 mg nocte) in patients with severe chronic renal failure. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387982/),[ng] / [ml],1.90,151274,DB01198,Zopiclone
,2387982,AUC,The AUC values in CRF patients were also significantly increased during the seventh day (742 +/- 212 h ng/ml) compared to healthy subjects (408 +/- 66.5 h ng/ml) and the elimination half-life of zopiclone was also longer in CRF patients (about 8 h) than in the reference group (about 5 h).,Steady state pharmacokinetics of zopiclone during multiple oral dosing (7.5 mg nocte) in patients with severe chronic renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387982/),[h·ng] / [ml],742,151275,DB01198,Zopiclone
,2387982,AUC,The AUC values in CRF patients were also significantly increased during the seventh day (742 +/- 212 h ng/ml) compared to healthy subjects (408 +/- 66.5 h ng/ml) and the elimination half-life of zopiclone was also longer in CRF patients (about 8 h) than in the reference group (about 5 h).,Steady state pharmacokinetics of zopiclone during multiple oral dosing (7.5 mg nocte) in patients with severe chronic renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387982/),[h·ng] / [ml],408,151276,DB01198,Zopiclone
,2387982,elimination half-life,The AUC values in CRF patients were also significantly increased during the seventh day (742 +/- 212 h ng/ml) compared to healthy subjects (408 +/- 66.5 h ng/ml) and the elimination half-life of zopiclone was also longer in CRF patients (about 8 h) than in the reference group (about 5 h).,Steady state pharmacokinetics of zopiclone during multiple oral dosing (7.5 mg nocte) in patients with severe chronic renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387982/),h,8,151277,DB01198,Zopiclone
,2387982,elimination half-life,The AUC values in CRF patients were also significantly increased during the seventh day (742 +/- 212 h ng/ml) compared to healthy subjects (408 +/- 66.5 h ng/ml) and the elimination half-life of zopiclone was also longer in CRF patients (about 8 h) than in the reference group (about 5 h).,Steady state pharmacokinetics of zopiclone during multiple oral dosing (7.5 mg nocte) in patients with severe chronic renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387982/),h,5,151278,DB01198,Zopiclone
,2387982,accumulation ratios,"Nevertheless, the accumulation ratios remained similar in the two groups (1.09 +/- 0.18 in CRF patients and 1.02 +/- 0.2 in healthy subjects).",Steady state pharmacokinetics of zopiclone during multiple oral dosing (7.5 mg nocte) in patients with severe chronic renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387982/),,1.09,151279,DB01198,Zopiclone
,2387982,accumulation ratios,"Nevertheless, the accumulation ratios remained similar in the two groups (1.09 +/- 0.18 in CRF patients and 1.02 +/- 0.2 in healthy subjects).",Steady state pharmacokinetics of zopiclone during multiple oral dosing (7.5 mg nocte) in patients with severe chronic renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387982/),,1.02,151280,DB01198,Zopiclone
<,12608888,half-life,"According to their pharmacokinetic profile, benzodiazepines can be classified into three groups: short half-life (<3 hours), medium half-life (8-24 hours) and long half-life (>24 hours).","New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12608888/),h,3,152307,DB01198,Zopiclone
,12608888,half-life,"According to their pharmacokinetic profile, benzodiazepines can be classified into three groups: short half-life (<3 hours), medium half-life (8-24 hours) and long half-life (>24 hours).","New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12608888/),h,8-24,152308,DB01198,Zopiclone
>,12608888,half-life,"According to their pharmacokinetic profile, benzodiazepines can be classified into three groups: short half-life (<3 hours), medium half-life (8-24 hours) and long half-life (>24 hours).","New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12608888/),h,24,152309,DB01198,Zopiclone
,12608888,half-life,Zaleplon is characterised by an ultrashort half-life (approximately 1 hour).,"New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12608888/),h,1,152310,DB01198,Zopiclone
,12608888,half-lives,"Zolpidem and zopiclone have longer half-lives (approximately 2.4 and 5 hours, respectively).","New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12608888/),h,2.4,152311,DB01198,Zopiclone
,12608888,half-lives,"Zolpidem and zopiclone have longer half-lives (approximately 2.4 and 5 hours, respectively).","New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12608888/),h,5,152312,DB01198,Zopiclone
,11902799,ratios,"Conversely, after administration of (-)-zopiclone, both enantiomers were found in plasma and brain with (+)-zopiclone/(-)-zopiclone ratios of 1 and 8.4 in plasma and brain, respectively.",Stereoselective distribution and stereoconversion of zopiclone enantiomers in plasma and brain tissues in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11902799/),,1,165726,DB01198,Zopiclone
,11902799,ratios,"Conversely, after administration of (-)-zopiclone, both enantiomers were found in plasma and brain with (+)-zopiclone/(-)-zopiclone ratios of 1 and 8.4 in plasma and brain, respectively.",Stereoselective distribution and stereoconversion of zopiclone enantiomers in plasma and brain tissues in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11902799/),,8,165727,DB01198,Zopiclone
,18313371,ch,The method had a chromatographic run time of 4.5 min and linear calibration curves over the concentration range of 0.5-150 ng/mL for both zopiclone and N-desmethyl zopiclone and 1-150 ng/mL for zopiclone-N-oxide.,"HPLC-ESI-MS/MS validated method for simultaneous quantification of zopiclone and its metabolites, N-desmethyl zopiclone and zopiclone-N-oxide in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18313371/),min,4.5,168041,DB01198,Zopiclone
,18313371,run time,The method had a chromatographic run time of 4.5 min and linear calibration curves over the concentration range of 0.5-150 ng/mL for both zopiclone and N-desmethyl zopiclone and 1-150 ng/mL for zopiclone-N-oxide.,"HPLC-ESI-MS/MS validated method for simultaneous quantification of zopiclone and its metabolites, N-desmethyl zopiclone and zopiclone-N-oxide in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18313371/),min,4.5,168042,DB01198,Zopiclone
> or =,18313371,recoveries,The recoveries calculated for the analytes and internal standard were > or = 90% from spiked plasma samples.,"HPLC-ESI-MS/MS validated method for simultaneous quantification of zopiclone and its metabolites, N-desmethyl zopiclone and zopiclone-N-oxide in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18313371/),%,90,168043,DB01198,Zopiclone
greater,6669634,oral bioavailability,"ZD is rapidly and efficiently absorbed: its oral bioavailability was greater than 75% in all species except rats, where a first-pass effect of about 65% was recorded.",Pharmacokinetics and metabolism of zopiclone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6669634/),%,75,171136,DB01198,Zopiclone
,6669634,Plasma protein binding,Plasma protein binding is about 45%.,Pharmacokinetics and metabolism of zopiclone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6669634/),%,45,171137,DB01198,Zopiclone
,6669634,terminal half-life,"Plasma kinetics of ZD are generally well described by a two-compartment open model; in man, terminal half-life is 4-5 h; total body clearance is large (300 ml/mn), renal clearance very low (10 ml/min).",Pharmacokinetics and metabolism of zopiclone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6669634/),h,4-5,171138,DB01198,Zopiclone
,6669634,total body clearance,"Plasma kinetics of ZD are generally well described by a two-compartment open model; in man, terminal half-life is 4-5 h; total body clearance is large (300 ml/mn), renal clearance very low (10 ml/min).",Pharmacokinetics and metabolism of zopiclone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6669634/),[ml] / [mn],300,171139,DB01198,Zopiclone
,6669634,renal clearance,"Plasma kinetics of ZD are generally well described by a two-compartment open model; in man, terminal half-life is 4-5 h; total body clearance is large (300 ml/mn), renal clearance very low (10 ml/min).",Pharmacokinetics and metabolism of zopiclone. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6669634/),[ml] / [min],10,171140,DB01198,Zopiclone
,6669634,milk/plasma ratio,"In nursing mothers, milk and plasma kinetics of ZD are similar with a milk/plasma ratio around 0.80.",Pharmacokinetics and metabolism of zopiclone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6669634/),,0.80,171141,DB01198,Zopiclone
,2874974,half-life,"Minimal impairment of psychomotor skills and mental acuity occurs in the morning after a bedtime dose of zopiclone, which has a short half-life of about 5 hours and no long acting metabolites.",Zopiclone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2874974/),h,5,173477,DB01198,Zopiclone
greater,7188377,oral bioavailability,"ZD is rapidly and efficiently absorbed: its oral bioavailability was greater than 75% in all species except rats, where a first-pass effect of about 65% was recorded.",Pharmacokinetics and metabolism of zopiclone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7188377/),%,75,197667,DB01198,Zopiclone
,7188377,Plasma protein binding,Plasma protein binding is about 45%.,Pharmacokinetics and metabolism of zopiclone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7188377/),%,45,197668,DB01198,Zopiclone
,7188377,terminal half-life,"Plasma kinetics of ZD are generally well described by a two-compartment open model; in man, terminal half-life is 4-5 h; total body clearance is large (300 ml/mn), renal clearance very low (10 ml/min).",Pharmacokinetics and metabolism of zopiclone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7188377/),h,4-5,197669,DB01198,Zopiclone
,7188377,total body clearance,"Plasma kinetics of ZD are generally well described by a two-compartment open model; in man, terminal half-life is 4-5 h; total body clearance is large (300 ml/mn), renal clearance very low (10 ml/min).",Pharmacokinetics and metabolism of zopiclone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7188377/),[ml] / [mn],300,197670,DB01198,Zopiclone
,7188377,renal clearance,"Plasma kinetics of ZD are generally well described by a two-compartment open model; in man, terminal half-life is 4-5 h; total body clearance is large (300 ml/mn), renal clearance very low (10 ml/min).",Pharmacokinetics and metabolism of zopiclone. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7188377/),[ml] / [min],10,197671,DB01198,Zopiclone
,7188377,milk/plasma ratio,"In nursing mothers, milk and plasma kinetics of ZD are similar with a milk/plasma ratio around 0.80.",Pharmacokinetics and metabolism of zopiclone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7188377/),,0.80,197672,DB01198,Zopiclone
,8787948,bioavailability,"After oral administration, zopiclone is rapidly absorbed, with a bioavailability of approximately 80%.",Clinical pharmacokinetics of zopiclone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787948/),%,80,207436,DB01198,Zopiclone
,8787948,plasma protein binding,The plasma protein binding of zopiclone has been reported to be between 45 and 80%.,Clinical pharmacokinetics of zopiclone. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787948/),%,45 and 80,207437,DB01198,Zopiclone
,8787948,terminal elimination half-life (t1/2z),The terminal elimination half-life (t1/2z) of zopiclone ranges from 3.5 to 6.5 hours.,Clinical pharmacokinetics of zopiclone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787948/),h,3.5 to 6.5,207438,DB01198,Zopiclone
,9433391,total area under the plasma zolpidem concentration-time curve,The total area under the plasma zolpidem concentration-time curve after administration of rifampin was 27% of that after administration of placebo (336 +/- 67 versus 1202 +/- 157 ng.hr/ml [mean value +/- SEM; p < 0.01]).,Rifampin reduces plasma concentrations and effects of zolpidem. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),[h·ng] / [ml],336,212367,DB01198,Zopiclone
,9433391,total area under the plasma zolpidem concentration-time curve,The total area under the plasma zolpidem concentration-time curve after administration of rifampin was 27% of that after administration of placebo (336 +/- 67 versus 1202 +/- 157 ng.hr/ml [mean value +/- SEM; p < 0.01]).,Rifampin reduces plasma concentrations and effects of zolpidem. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),[h·ng] / [ml],1202,212368,DB01198,Zopiclone
,9433391,peak plasma concentration,"Rifampin decreased the peak plasma concentration of zolpidem by 58%, that is, from 293 +/- 61 to 117 +/- 25 ng/ml (p < 0.01) and the elimination half-life from 2.5 +/- 0.2 to 1.6 +/- 0.1 hours (p < 0.01).",Rifampin reduces plasma concentrations and effects of zolpidem. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),[ng] / [ml],293,212369,DB01198,Zopiclone
,9433391,peak plasma concentration,"Rifampin decreased the peak plasma concentration of zolpidem by 58%, that is, from 293 +/- 61 to 117 +/- 25 ng/ml (p < 0.01) and the elimination half-life from 2.5 +/- 0.2 to 1.6 +/- 0.1 hours (p < 0.01).",Rifampin reduces plasma concentrations and effects of zolpidem. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),[ng] / [ml],117,212370,DB01198,Zopiclone
,9433391,elimination half-life,"Rifampin decreased the peak plasma concentration of zolpidem by 58%, that is, from 293 +/- 61 to 117 +/- 25 ng/ml (p < 0.01) and the elimination half-life from 2.5 +/- 0.2 to 1.6 +/- 0.1 hours (p < 0.01).",Rifampin reduces plasma concentrations and effects of zolpidem. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),h,2.5,212371,DB01198,Zopiclone
,9433391,elimination half-life,"Rifampin decreased the peak plasma concentration of zolpidem by 58%, that is, from 293 +/- 61 to 117 +/- 25 ng/ml (p < 0.01) and the elimination half-life from 2.5 +/- 0.2 to 1.6 +/- 0.1 hours (p < 0.01).",Rifampin reduces plasma concentrations and effects of zolpidem. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),h,1.6,212372,DB01198,Zopiclone
,23404347,half-life,Their pharmacokinetics approach those of the ideal hypnotic with rapid onset within 30 min and short half-life (1-7 h).,The clinical and forensic toxicology of Z-drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23404347/),h,1-7,214122,DB01198,Zopiclone
,2206788,milk/plasma AUC ratio,2. The milk/plasma AUC ratio of zopiclone was 0.51 +/- 0.09 (mean +/- s.d.).,The excretion of zopiclone into breast milk. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206788/),,0.51,224423,DB01198,Zopiclone
,16373464,relative bioavailability,The relative bioavailability of oral racemic zopiclone is about 80%.,Eszopiclone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16373464/),%,80,230893,DB01198,Zopiclone
,16373464,peak serum concentrations,"Eszopiclone is rapidly absorbed after oral administration, with peak serum concentrations ranging from 1 to 1.3 hours.",Eszopiclone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16373464/),h,1 to 1.3,230894,DB01198,Zopiclone
,15005637,bioavailability,"Although zaleplon has a much lower bioavailability (30%), the treatment dose is similar to zolpidem and zopiclone (bioavilaibility of 70%) because of the increased potency of zaleplon.","Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005637/),%,30,236145,DB01198,Zopiclone
,15005637,bioavilaibility,"Although zaleplon has a much lower bioavailability (30%), the treatment dose is similar to zolpidem and zopiclone (bioavilaibility of 70%) because of the increased potency of zaleplon.","Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005637/),%,70,236146,DB01198,Zopiclone
,23126273,half-life,"The mean half-life in healthy nonelderly individuals (6.1 h) is prolonged in the elderly, in patients with hepatic insufficiency, and by coadministration of CYP3A inhibitors.",Pharmacokinetic evaluation of eszopiclone: clinical and therapeutic implications. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23126273/),h,6.1,244675,DB01198,Zopiclone
,23038043,Cmax,"The main pharmacokinetic parameters of eszopiclone after single-dose administration were as follows: doses of 1.5, 3 and 6 mg; Cmax of 18.08±4.65, 38.29±15.41 and 76.38±23.34 ng/ml; Tmax of 0.94±0.39, 1.04±0.63 and 1.08±0.51 h; AUC0-24 of 110.90±23.06, 227.36±62.41 and 504.10±140.13 ng*h/ml; elimination half-lives of 5.84±1.03, 5.53±1.91 and 6.17±1.23 h.",Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038043/),[ng] / [ml],18.08,266565,DB01198,Zopiclone
,23038043,Cmax,"The main pharmacokinetic parameters of eszopiclone after single-dose administration were as follows: doses of 1.5, 3 and 6 mg; Cmax of 18.08±4.65, 38.29±15.41 and 76.38±23.34 ng/ml; Tmax of 0.94±0.39, 1.04±0.63 and 1.08±0.51 h; AUC0-24 of 110.90±23.06, 227.36±62.41 and 504.10±140.13 ng*h/ml; elimination half-lives of 5.84±1.03, 5.53±1.91 and 6.17±1.23 h.",Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038043/),[ng] / [ml],38.29,266566,DB01198,Zopiclone
,23038043,Cmax,"The main pharmacokinetic parameters of eszopiclone after single-dose administration were as follows: doses of 1.5, 3 and 6 mg; Cmax of 18.08±4.65, 38.29±15.41 and 76.38±23.34 ng/ml; Tmax of 0.94±0.39, 1.04±0.63 and 1.08±0.51 h; AUC0-24 of 110.90±23.06, 227.36±62.41 and 504.10±140.13 ng*h/ml; elimination half-lives of 5.84±1.03, 5.53±1.91 and 6.17±1.23 h.",Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038043/),[ng] / [ml],76.38,266567,DB01198,Zopiclone
,23038043,Tmax,"The main pharmacokinetic parameters of eszopiclone after single-dose administration were as follows: doses of 1.5, 3 and 6 mg; Cmax of 18.08±4.65, 38.29±15.41 and 76.38±23.34 ng/ml; Tmax of 0.94±0.39, 1.04±0.63 and 1.08±0.51 h; AUC0-24 of 110.90±23.06, 227.36±62.41 and 504.10±140.13 ng*h/ml; elimination half-lives of 5.84±1.03, 5.53±1.91 and 6.17±1.23 h.",Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038043/),h,0.94,266568,DB01198,Zopiclone
,23038043,Tmax,"The main pharmacokinetic parameters of eszopiclone after single-dose administration were as follows: doses of 1.5, 3 and 6 mg; Cmax of 18.08±4.65, 38.29±15.41 and 76.38±23.34 ng/ml; Tmax of 0.94±0.39, 1.04±0.63 and 1.08±0.51 h; AUC0-24 of 110.90±23.06, 227.36±62.41 and 504.10±140.13 ng*h/ml; elimination half-lives of 5.84±1.03, 5.53±1.91 and 6.17±1.23 h.",Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038043/),h,1.04,266569,DB01198,Zopiclone
,23038043,Tmax,"The main pharmacokinetic parameters of eszopiclone after single-dose administration were as follows: doses of 1.5, 3 and 6 mg; Cmax of 18.08±4.65, 38.29±15.41 and 76.38±23.34 ng/ml; Tmax of 0.94±0.39, 1.04±0.63 and 1.08±0.51 h; AUC0-24 of 110.90±23.06, 227.36±62.41 and 504.10±140.13 ng*h/ml; elimination half-lives of 5.84±1.03, 5.53±1.91 and 6.17±1.23 h.",Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038043/),h,1.08,266570,DB01198,Zopiclone
,23038043,AUC0-24,"The main pharmacokinetic parameters of eszopiclone after single-dose administration were as follows: doses of 1.5, 3 and 6 mg; Cmax of 18.08±4.65, 38.29±15.41 and 76.38±23.34 ng/ml; Tmax of 0.94±0.39, 1.04±0.63 and 1.08±0.51 h; AUC0-24 of 110.90±23.06, 227.36±62.41 and 504.10±140.13 ng*h/ml; elimination half-lives of 5.84±1.03, 5.53±1.91 and 6.17±1.23 h.",Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038043/),[h·ng] / [ml],110.90,266571,DB01198,Zopiclone
,23038043,AUC0-24,"The main pharmacokinetic parameters of eszopiclone after single-dose administration were as follows: doses of 1.5, 3 and 6 mg; Cmax of 18.08±4.65, 38.29±15.41 and 76.38±23.34 ng/ml; Tmax of 0.94±0.39, 1.04±0.63 and 1.08±0.51 h; AUC0-24 of 110.90±23.06, 227.36±62.41 and 504.10±140.13 ng*h/ml; elimination half-lives of 5.84±1.03, 5.53±1.91 and 6.17±1.23 h.",Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038043/),[h·ng] / [ml],227.36,266572,DB01198,Zopiclone
,23038043,AUC0-24,"The main pharmacokinetic parameters of eszopiclone after single-dose administration were as follows: doses of 1.5, 3 and 6 mg; Cmax of 18.08±4.65, 38.29±15.41 and 76.38±23.34 ng/ml; Tmax of 0.94±0.39, 1.04±0.63 and 1.08±0.51 h; AUC0-24 of 110.90±23.06, 227.36±62.41 and 504.10±140.13 ng*h/ml; elimination half-lives of 5.84±1.03, 5.53±1.91 and 6.17±1.23 h.",Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038043/),[h·ng] / [ml],504.10,266573,DB01198,Zopiclone
,23038043,elimination half-lives,"The main pharmacokinetic parameters of eszopiclone after single-dose administration were as follows: doses of 1.5, 3 and 6 mg; Cmax of 18.08±4.65, 38.29±15.41 and 76.38±23.34 ng/ml; Tmax of 0.94±0.39, 1.04±0.63 and 1.08±0.51 h; AUC0-24 of 110.90±23.06, 227.36±62.41 and 504.10±140.13 ng*h/ml; elimination half-lives of 5.84±1.03, 5.53±1.91 and 6.17±1.23 h.",Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038043/),h,5.84,266574,DB01198,Zopiclone
,23038043,elimination half-lives,"The main pharmacokinetic parameters of eszopiclone after single-dose administration were as follows: doses of 1.5, 3 and 6 mg; Cmax of 18.08±4.65, 38.29±15.41 and 76.38±23.34 ng/ml; Tmax of 0.94±0.39, 1.04±0.63 and 1.08±0.51 h; AUC0-24 of 110.90±23.06, 227.36±62.41 and 504.10±140.13 ng*h/ml; elimination half-lives of 5.84±1.03, 5.53±1.91 and 6.17±1.23 h.",Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038043/),h,5.53,266575,DB01198,Zopiclone
,23038043,elimination half-lives,"The main pharmacokinetic parameters of eszopiclone after single-dose administration were as follows: doses of 1.5, 3 and 6 mg; Cmax of 18.08±4.65, 38.29±15.41 and 76.38±23.34 ng/ml; Tmax of 0.94±0.39, 1.04±0.63 and 1.08±0.51 h; AUC0-24 of 110.90±23.06, 227.36±62.41 and 504.10±140.13 ng*h/ml; elimination half-lives of 5.84±1.03, 5.53±1.91 and 6.17±1.23 h.",Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038043/),h,6.17,266576,DB01198,Zopiclone
,23038043,Css_max,"After multiple-dose administration, the steady-state levels of eszopiclone were achieved by the 4th day, and the main pharmacokinetic parameters were Css_max at 33.43±5.63 ng/ml and AUCss (0-24) at 263.30±51.21 ng*h/ml.",Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038043/),[ng] / [ml],33.43,266577,DB01198,Zopiclone
,23038043,AUCss (0-24),"After multiple-dose administration, the steady-state levels of eszopiclone were achieved by the 4th day, and the main pharmacokinetic parameters were Css_max at 33.43±5.63 ng/ml and AUCss (0-24) at 263.30±51.21 ng*h/ml.",Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038043/),[h·ng] / [ml],263.30,266578,DB01198,Zopiclone
,7833227,peak time,The peak time of zopiclone concentration was reduced from 2 to 1 h (P < 0.001).,The effect of erythromycin on the pharmacokinetics and pharmacodynamics of zopiclone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833227/),h,2,269776,DB01198,Zopiclone
,7833227,peak time,The peak time of zopiclone concentration was reduced from 2 to 1 h (P < 0.001).,The effect of erythromycin on the pharmacokinetics and pharmacodynamics of zopiclone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833227/),h,1,269777,DB01198,Zopiclone
